Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

Abstract

In summary, it is unlikely that in the near future we will have sufficient prospective randomized studies to resolve definitively the dilemma of inhibitor induction. Therefore, both physicians and patients need to recognize that choosing a recombinant therapeutic product may well increase the risk of this major complication of therapy. © 2004 International Society on Thrombosis and Haemostasis.